Anvatabart opadotin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Anvatabart opadotin
- DrugBank Accession Number
- DB18290
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Arx-788 (anti-her2 mab paf- mmaf toxin oxime conjugate)
- gamma1 heavy chain humanized (1-449) [VH humanized (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01, G1m17,1 (CH1 A1.4>F (pAF) (121), K120 (217) (121- 218), hinge 1-15 (219
- Immunoglobulin G1 [121-(4-acetylphenylalanine),de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal Amab788 γ1-chain), disulfide with human-Mus musculus monoclonal Amab788 κ-chain, dimer, 121,121′-dioxime
- Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated at two engineered sites via a stable
- External IDs
- ARX 788
- ARX-788
- ARX788
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- B2KH16FA7H
- CAS number
- 2636710-07-9
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Not Yet Recruiting Treatment HER2 Low Breast Carcinoma / Hormone Receptor Positive Breast Carcinoma / Triple-Negative Breast Cancer 1 2 Recruiting Treatment Angiosarcoma / Breast Cancer / Breast Neoplasms / Breast Tumor / HER2/Neu-positive Breast Cancer / Hormone Receptor Negative Tumor / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Locally Advanced Breast Cancer (LABC) / Stage I Breast Cancer / Triple-Negative Breast Cancer 1 2 Recruiting Treatment Breast Neoplasms 1 2 Recruiting Treatment HER2-low Breast Cancer 1 2 Recruiting Treatment Metastatic Breast Cancer With HER2 Positive 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at September 15, 2023 21:31 / Updated at September 17, 2023 04:15